BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.17.5.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Global Biodefense
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20191027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20211031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20190310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20191103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200424
DTEND;VALUE=DATE:20200425
DTSTAMP:20200222T220028Z
CREATED:20200222T215710Z
LAST-MODIFIED:20200222T220028Z
UID:40125-1587686400-1587772799@globalbiodefense.com
SUMMARY:Quickfire Challenge Applications Due: JLABS Pediatric Influenza Innovations
DESCRIPTION:Innovators within the fields of pediatric oncology\, pediatric surgery and influenza are invited to submit innovative ideas for a total of up to $150\,000 in grant funding; one year of residency at JLABS @ Washington\, DC with the use of a bench\, workstation\, and access to the JLABS @ Washington\, DC community; and mentorship from experts at the Johnson & Johnson Family of Companies. \nThe submission deadline is 24 April 2020. Please visit the JLABS website for more information.
URL:https://globalbiodefense.com/event/quickfire-challenge-applications-due-jlabs-pediatric-influenza-innovations/
LOCATION:Global Biodefense Calendar
CATEGORIES:Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20200421T130000
DTEND;TZID=Europe/London:20200421T140000
DTSTAMP:20240623T192624Z
CREATED:20200406T161624Z
LAST-MODIFIED:20240623T192624Z
UID:42642-1587474000-1587477600@globalbiodefense.com
SUMMARY:DASA Biosensing Across Wide Areas Phase 2 Launch
DESCRIPTION:Join the Defence and Security Accelerator for a dial-in on 21 April 2020\, 1pm to 2pm. The competition team will provide a short briefing on the Biosensing Across Wide Areas Phase 2 competition followed by an open forum Q&A session. \nOne to Ones\nThere will be two opportunities for One to One dial-in sessions with the competition team: \n\nWednesday 21 April 2020 –  2.30pm to 4pm: Three slots available\nThursday 22 April 2020 – 1pm to 3pm: Four slots available\n\nThese pre-bookable 20 minute one to one slots will be with the competition team to discuss questions specific to your proposal. Slots are on a first come\, first serve basis. \nPlease note: \n\na separate link will be sent to you on your ticket confirmation to register for a one to one slot\ndetails of the dial in will be sent before the meeting commences\nif the event is oversubscribed\, we may place a limitation on the number of attendees from a single organisation\n\n// \nREAD MORE: UK Launches Wide-Area Biosensor Competition
URL:https://globalbiodefense.com/event/dasa-biosensing-across-wide-areas-phase-2-launch/
CATEGORIES:Conference,Industry Day,Webinar-Webcast
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2020/04/97aef6bbedcf01db65e877ee6755e43d.jpg
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200420
DTEND;VALUE=DATE:20200425
DTSTAMP:20200323T183614Z
CREATED:20191219T152600Z
LAST-MODIFIED:20200323T183614Z
UID:35622-1587340800-1587772799@globalbiodefense.com
SUMMARY:POSTPONED | NO NEW DATE - BSL-4 Training: Achieving Data Quality and Integrity in Maximum Containment Laboratories
DESCRIPTION:The FDA and the University of Texas Medical Branch\, Galveston National Laboratory (UTMB) will host this year’s annual training course on how to meet GLP requirements in BSL-4 facilities from April 20-24\, 2020 at the National Institutes of Health (NIH) in Bethesda\, Maryland. \nScientists working to develop Medical Countermeasures (MCMs) against several high-priority biological threat agents are at high risk of aerosol-transmitted laboratory infection and life-threatening disease\, as there are no vaccines or treatments for these agents. Accordingly\, much of the work to develop MCMs for these high-priority agents must be done in high and maximum biosafety level (BSL)-4 laboratories to prevent the agents from being released into the environment\, and to provide maximum safety for the scientists. \nThe unique challenges of BSL-4\nWhile necessary to ensure lab worker safety and prevent accidental release of dangerous pathogens\, BSL-4 environments pose unique challenges to developing MCMs. For example\, data generated to support a regulatory submission to FDA must be collected in accordance with quality systems\, like good laboratory practice (GLP) regulations\, to be useful and reliable\, and to facilitate FDA review to ensure safety and efficacy. \nHowever\, meeting data quality and integrity standards like GLP in a BSL-4 environment is challenging. Current practice is often inconsistent among laboratories due to technological infrastructure\, available internal standard operating procedures\, level of regulatory awareness\, and individual breadth of experience and training. And completing even routine lab tasks in a protective BSL-4 suit can be difficult—imagine\, for example\, trying to pick up a small item\, like a toothpick\, while wearing two pairs of thick gloves. \nTo help address the challenges associated with ensuring data quality and integrity in regulated studies conducted in BSL-4 laboratories to support MCM development\, FDA and the University of Texas Medical Branch\, Galveston National Laboratory (UTMB) collaborate to provide an annual training course on how to meet GLP requirements in BSL-4 facilities (“data quality course”). \n\nThis popular course offers a unique opportunity for the regulatory and scientific communities to discuss complex issues in an interactive environment and identify and share best practices for ensuring data quality and integrity in BSL-4 facilities. \n\nIn addition to UTMB and FDA\, other federal partners from the National Interagency Confederation for Biological Research (NICBR) provide support and resources for this course. These partners include: \n\nFrom the National Institutes of Health\n\nOffice of the Director\nNational Institute of Allergy and Infectious Diseases (NIAID)\nNational Cancer Institute (NCI)\n\n\nFrom the Department of Defense\n\nU.S. Army Medical Research and Materiel Command (USAMRMC)\n\n\n\n\nFrom the Department of Homeland Security\n\nNational Biodefense Analysis and Countermeasures Center (NBACC)\n\n\n\nHistory and new additions\nSince the data quality course began in 2013\, it has quickly reached capacity each year. In its first five years\, 269 participants completed the course. \nIn September 2017\, the FDA Medical Countermeasures Initiative (MCMi) renewed the grant  to continue the data quality course for an additional five years\, from 2018-2022. UTMB and FDA will also expand on-demand online offerings\, adding data quality-related good clinical practices (GCP) training and other courses to meet the needs of researchers responding to emerging infectious disease outbreaks. \nCourse description\nThe week-long\, data quality course is designed to help researchers who conduct studies intended to support approval under the Animal Rule\, which may be used to grant marketing approval of certain products when human challenge studies would not be ethical or feasible. \nThe course includes expert lectures and hands-on laboratory activities conducted in BSL-2 and BSL-4 training laboratories to emphasize the differences between biosafety levels\, and the complexity of conducting laboratory activities in a BSL-4 environment. An online training module on GLP regulations (21 CFR Part 58) is included as a course pre-requisite. For additional information\, visit the official UTMB course website \nTopics covered include: \n\nAnimal Rule regulations\, and clinical applications of Animal Rule studies\nAssay validation\nBSL-2/3/4 comparison\, with hands-on simulations\nBSL-4 equipment\, with hands-on work in a BSL-4 training lab\nDisease agent characterization\nGLP regulations\nGood documentation practices\nInstitutional Animal Care and Use Committee (IACUC) protocols\nTelemetry\nSupportive care\nSurrogate endpoints\nTesting facility management\nVeterinary pathology\nIntegration of quality assurance (QA) in BSL-4 studies\nAdvancement of MCMs on the international stage\n\nWho may attend?\nFDA welcomes participants from government\, industry\, and academia. We welcome international participation as well; attendees in previous years have included representatives from international public health agencies. Attendees typically include: \n\nPolicy-makers\nMCM product sponsors (industry)\nQuality assurance personnel\nRegulators\nReviewers\nScientists\nVeterinarians\n\nPre-requisites include GLP and IACUC training that are available to course attendees. \nCourse Cost and Availability\nThere are no registration fees for this FDA-sponsored course\, however\, seats are limited\, and course attendees are invited based upon diversity of roles\, responsibilities\, and organization. Interested participants will be placed on a waitlist once seats are filled. \nRELATED INFORMATION \n\nInformation about the course from UTMB\nSister course: Achieving Data Quality and Integrity in Clinical Trials Involving High-Consequence Pathogens\nPrevious course offerings\nView photos from the 2015 course on Flickr
URL:https://globalbiodefense.com/event/bsl-4-training-achieving-data-quality-and-integrity-in-maximum-containment-laboratories/
LOCATION:National Institutes of Health (NIH)\, Bethesda\, MD\, United States
CATEGORIES:Training
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200415T170000
DTEND;TZID=America/New_York:20200415T183000
DTSTAMP:20240623T192248Z
CREATED:20200414T182247Z
LAST-MODIFIED:20240623T192248Z
UID:43055-1586970000-1586975400@globalbiodefense.com
SUMMARY:APHA and National Academy of Medicine Webinar: Crisis Standards of Care During COVID-19
DESCRIPTION:Brought to you by the American Public Health Association and the National Academy of Medicine\, this webinar series is exploring the state of the science surrounding the current outbreak of COVID-19 in the United States and globally\, with a focus on the emerging evidence on how to best mitigate its impact. Hear from trusted experts in such fields as public health\, infectious disease\, risk communication\, and crisis standards of care. \nWebinar #4: Crisis Standards of Care During COVID-19\nWednesday\, April 15\, 5-6:30 p.m. ET \nThe fourth COVID-19 Conversations webinar will provide an overview of crisis standards of care during a pandemic\, challenges for adapting such standards to rapidly evolving clinical care guidelines\, practical considerations for state health departments and hospital systems\, and ethical considerations for decision-making while enacting crisis standards of care. \nThe expert panel for this webinar includes: \n\nJohn L. Hick\, MD\, is a faculty emergency physician at Hennepin County Medical Center and an Associate Professor of Emergency Medicine at the University of Minnesota Medical School. He serves as the Associate Medical Director for Hennepin County Medical Services and Medical Director for Emergency Preparedness at HCMC. He is medical advisor to the Minneapolis/St. Paul Metropolitan Medical Response System. He also serves the Minnesota Department of Health as the Medical Director for the Office of Emergency Preparedness and Medical Director for Hospital Bioterrorism Preparedness. He is the founder and past chair of the Minneapolis/St. Paul Metropolitan Health Compact\, a 29-hospital mutual aid and planning group. The regional program was recognized with a $2.5 million competitive HHS preparedness grant in 2007. Hick traveled to Greece as part of a 15-member CDC/HHS team to assist with health care system preparations for the 2004 Summer Olympics. He continues to work with HHS and other agencies on issues of hospital surge capacity planning\, adjusted standards of care in disasters\, and preparedness for nuclear terrorism.\n\n  \n\nRebecca E. Gee\, MD\, is the Secretary of the Louisiana Department of Health\, the state’s largest agency with a budget of $14 billion\, and Gratis Assistant Professor at the LSU Schools of Public Health and Medicine. Her oversight responsibilities include public health and other direct service programs for citizens in needs such as behavioral health\, developmental disabilities\, aging and adult services\, emergency preparedness ad the Medicaid program. Her Medicaid expansion work resulted in an additiona 500\,000+ Louisiana residents being newly insured and the launch of a dashboard to measure access to health care services that has become a national model used in other states. She is an OB/GYN\, trained policy expert and previously served as the director of the Birth Outcomes Initiative\, where she led the charge to decrease infant mortality and prematurity statewide — an effort that in part led to a 25% reduction in infant mortality\, an 85% drop in elective deliveries before 39 weeks and a 10% drop in NICU admissions.\n\n  \n\nJeffrey Kahn\, PhD\, MD\, is the is the Andreas C. Dracopoulos Director of the Johns Hopkins Berman Institute of Bioethics and the inaugural Robert Henry Levi and Ryda Hecht Levi Professor of Bioethics and Public Policy. He is also Professor in the Department of Health Policy and Management of the Johns Hopkins Bloomberg School of Public Health. He works in a variety of areas of bioethics\, exploring the intersection of ethics and health/science policy. Kahn has served on numerous state and federal advisory panels and is currently chair of National Academies of Sciences\, Engineering\, and Medicine’s Board on Health Sciences Policy\, and has previously chaired its committee on the Use of Chimpanzees in Biomedical and Behavioral Research; the committee on Ethics Principles and Guidelines for Health Standards for Long Duration and Exploration Spaceflights; and a committee on the Ethical\, Social\, and Policy Considerations of Mitochondrial Replacement Techniques. He also formerly served as a member of the National Institutes of Health Recombinant DNA Advisory Committee. In addition to committee leadership and membership\, he is an elected member of the National Academy of Medicine and an elected Fellow of The Hastings Center. He was also the founding president of the Association of Bioethics Program Directors. He is a co-principal investigator with Berman Institute faculty member Gail Geller\, ScD\, MHS\, on GUIDE: Genomic Uses in Infectious Disease and Epidemics\, an NIH-funded project to study the largely unexplored ethical\, legal and social implications of genomics as applied to infectious disease.\n\n  \n\nLawrence “Larry” O. Gostin\, JD\, directs the O’Neill Institute for National and Global Health Law and is the founding O’Neil Chair in Global Health Law at Georgetown University. He served as associate dean for research at Georgetown Law from 2004-2008 and is professor of medicine at Georgetown University and professor of public health at Johns Hopkins University. He is director of the World Health Organization Collaborating Center on National and Global Health Law. Among his appointed posts at WHO\, he served on the Director-General’s Advisory Committee on Reforming the World Health Organization\, is on the International Health Regulations Roster of Experts and has served on many WHO expert advisory committees including on the Pandemic Influenza Preparedness Framework and on the WHO/Global Fund Blue Ribbon Expert Panel: The Equitable Access Initiative to develop a global health equity framework. He co-chairs the Lancet Commission on Global Health Law. He served on two global commissions to report on the lessons learned from the 2015 West African Ebola epidemic and was senior advisor to the United Nations Secretary General’s post-Ebola Commission. Gostin also served on the drafting team for the G-17 Summit in Tokyo in 2016\, focusing on global health security and universal health coverage.
URL:https://globalbiodefense.com/event/apha-and-national-academy-of-medicine-webinar-crisis-standards-of-care-during-covid-19/
CATEGORIES:Conference,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20200415T123000
DTEND;TZID=America/Los_Angeles:20200415T140000
DTSTAMP:20240623T231227Z
CREATED:20200408T174031Z
LAST-MODIFIED:20240623T231227Z
UID:42787-1586953800-1586959200@globalbiodefense.com
SUMMARY:Protecting Older Adults from the Harms of Social Isolation and Providing a Continuum of Care During COVID-19
DESCRIPTION:Join Trust for America’s Health (TFAH) on Wednesday\, April 15th for the webinar Protecting Against the Harms of Social Isolation During COVID-19. \nThe ongoing COVID-19 crisis presents unique challenges for the public health and aging sectors. While social distancing protects older adults who are at higher risk for complications from the virus\, the practice can exacerbate social isolation\, a longstanding issue for this population. \nAttendees will learn about the consequences of social isolation\, how the aging services sector has adapted its delivery models\, promising practices from the field and the importance of working with public health partners to address the needs of older adults.
URL:https://globalbiodefense.com/event/protecting-older-adults-from-the-harms-of-social-isolation-and-providing-a-continuum-of-care-during-covid-19/
CATEGORIES:Conference,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200409
DTEND;VALUE=DATE:20200410
DTSTAMP:20200211T235015Z
CREATED:20200211T234714Z
LAST-MODIFIED:20200211T235015Z
UID:39309-1586390400-1586476799@globalbiodefense.com
SUMMARY:Deadline for NIAID BAA Proposals: Advanced Development of Diagnostics for Biothreats and EID
DESCRIPTION:HHS-NIH-NIAID-BAA2020-1\nResearch Area 005: Advanced Development of Diagnostics for Biothreats and Emerging Infectious Diseases\n\nSupports advancing the development of novel\, rapid sample-to-answer candidate diagnostic products that will address biodefense and pandemic preparedness.\nNumber of Awards/Total Costs: NIAID estimates that one or more awards may be issued for this Research Area for a total cost of up to $2 million for the non-severable base work across all contracts (direct and indirect costs combined).\nDue Date: April 9\, 2020\, by 3 p.m. Eastern Time\n\nLearn more about this BAA in Funding News. \nGlobal Biodefense provides this information as a courtesy. Information is subject to change. Please check the funding opportunity sponsor website to verify the most current status.
URL:https://globalbiodefense.com/event/deadline-for-niaid-baa-proposals/
LOCATION:Global Biodefense Calendar
CATEGORIES:Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200409
DTEND;VALUE=DATE:20200410
DTSTAMP:20200211T234620Z
CREATED:20200211T234423Z
LAST-MODIFIED:20200211T234620Z
UID:39307-1586390400-1586476799@globalbiodefense.com
SUMMARY:Deadline for NIAID BAA Proposals: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases
DESCRIPTION:HHS-NIH-NIAID-BAA2020-1\nResearch Area 003: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases\nSupports development of vaccines 1) to address antibiotic resistant gram-negative bacteria focusing on but not limited to Burkholderia spp.\, Pseudomonas aeruginosa\, Francisella tularensis\, Yersinia pestis\, and E. coli\, and 2) for emerging viruses and pandemic preparedness that includes but is not limited to alphaviruses (e.g.\, Eastern Equine Encephalitis) and bunyaviruses (e.g.\, Rift Valley Fever Virus). \nDue Date: April 9\, 2020\, by 3 p.m. Eastern Time \nLearn more about this opportunity in here. \nGlobal Biodefense provides this information as a courtesy. Information is subject to change. Please check the funding opportunity sponsor website to verify the most current status.
URL:https://globalbiodefense.com/event/deadline-for-niaid-baa-proposals-advanced-development-of-vaccine-candidates-for-biodefense-and-emerging-infectious-diseases/
LOCATION:Global Biodefense Calendar
CATEGORIES:Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200409
DTEND;VALUE=DATE:20200410
DTSTAMP:20200211T233920Z
CREATED:20200211T233539Z
LAST-MODIFIED:20200211T233920Z
UID:39302-1586390400-1586476799@globalbiodefense.com
SUMMARY:Deadline for NIAID BAA Proposals: Therapeutic Products for Biodefense\, AMR Infections\, and Emerging Infectious Diseases
DESCRIPTION:HHS-NIH-NIAID-BAA2020-1\nResearch Area 004: Development of Therapeutic Products for Biodefense\, Anti-Microbial Resistant (AMR) Infections\, and Emerging Infectious Diseases\nSupports development of promising new therapeutics to address infections caused by NIAID Category A\, B\, and C priority pathogens and select bacterial and fungal infections identified in CDC’s report Antibiotic Resistance Threats in the United States 2019 \, including optimization\, preclinical (investigational new drug-enabling)\, and clinical trials that include Phase I and Phase II studies. \nDue Date: April 9\, 2020\, by 3 p.m. Eastern Time \nRead more on this opportunity in Funding News. \n  \nGlobal Biodefense provides this information as a courtesy. Information is subject to change. Please check the funding opportunity sponsor website to verify the most current status.
URL:https://globalbiodefense.com/event/deadline-for-niaid-baa-proposals-therapeutic-products-for-biodefense-amr-infections-and-emerging-infectious-diseases/
LOCATION:Global Biodefense Calendar
CATEGORIES:Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200409
DTEND;VALUE=DATE:20200410
DTSTAMP:20200211T233435Z
CREATED:20200211T233017Z
LAST-MODIFIED:20200211T233435Z
UID:39300-1586390400-1586476799@globalbiodefense.com
SUMMARY:Deadline for NIAID BAA Proposals: Development of Radiation/Nuclear Medical Countermeasures
DESCRIPTION:Research Area 001: Development of Radiation/Nuclear Medical Countermeasures (MCMs) HHS-NIH-NIAID-BAA2020-1\nThis research topic call for proposals is part of the 2020 NIAID Omnibus Broad Agency Announcement. \nIt supports the development of safe and effective MCMs to mitigate and/or treat tissue injuries resulting from exposure to ionizing radiation from a radiological or nuclear incident\, thereby leading to a reduction in radiation-associated morbidities and mortalities. \nDue Date: April 9\, 2020\, by 3 p.m. Eastern Time \nRead more about this opportunity in Funding News.
URL:https://globalbiodefense.com/event/deadline-for-niaid-baa-proposals-development-of-radiation-nuclear-medical-countermeasures/
LOCATION:Global Biodefense Calendar
CATEGORIES:Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200408T140000
DTEND;TZID=America/New_York:20200408T153000
DTSTAMP:20200402T171318Z
CREATED:20200402T170907Z
LAST-MODIFIED:20200402T171318Z
UID:42524-1586354400-1586359800@globalbiodefense.com
SUMMARY:NASEM Webinar: The Supply Chain and COVID-19
DESCRIPTION:COVID-19 has had a profound impact on supply chains for many different critical products worldwide. The pandemic has created major changes in freight flows and has challenged the ability to deliver both medical supplies and food. \nThe National Academies’ Transportation Research Board (TRB) is hosting a webinar on Wednesday\, April 8\, 2020\, from 2:00 to 3:30 PM Eastern that will explore the impacts of COVID-19 on the supply chain and logistics industries. Presenters will discuss lessons learned from past freight transportation and supply chain disruptions\, identify research that has been done to address resilience in the supply chain\, describe how to mitigate the economic impacts of these disruptions\, and provide commentary on current supply chain disruptions due to COVID-19. The webinar is free to attend\, but registration is required. You can follow the conversation on Twitter by using #COVID19 and #TRBwebinar. \nWebinar Participants\n• Moderated by: Mike Meyer\, WSP\, Principal Investigator for NCFRP Research Report 39: Freight Transportation Resilience in Response to Supply Chain Disruptions\n• Paul Bingham\, IHS Markit\, expert in supply chain logistics\, freight transportation\, and transportation economics\n• Anne Strauss-Wieder\, North Jersey Transportation Planning Authority\, expert in supply chain and freight movement\, transportation policy\, and maritime transportation \nWebinar Outline \n1. How the supply chain industry has responded to past disruptions\n2. Lessons learned from past disruptions and best practices for a resilient supply chain\n3. How supply chain and logistics managers can respond to disruptions from COVID-19\n4. Question and answer session\nThe first 60 minutes of the webinar will be for presentations and the final 30 minutes will be reserved for audience questions. \nResources about supply chain and logistics from TRB: \n\nNCFRP Research Report 39: Freight Transportation Resilience in Response to Supply Chain Disruptions\nE-Circular E-C259: International Transportation and Economic Development Conference 2018\nTR News article: Supply Chain Business Continuity\nTR News article: Aviation’s Evolving Role in a Changing Climate\nTRB Director Neil Pedersen’s message regarding COVID-19
URL:https://globalbiodefense.com/event/nasem-webinar-the-supply-chain-and-covid-19/
LOCATION:Virtual-Webcast
CATEGORIES:Conference,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200406
DTEND;VALUE=DATE:20200407
DTSTAMP:20200211T235602Z
CREATED:20200211T235220Z
LAST-MODIFIED:20200211T235602Z
UID:39312-1586131200-1586217599@globalbiodefense.com
SUMMARY:Proposals Due: Influenza Data Processing and Outreach
DESCRIPTION:If your small business has strong experience with scientific data processing and outreach\, consider sending a contract proposal to establish an Influenza Data Processing and Communication Center (iDPCC). \nThis solicitation recompetes and renames the current influenza DPCC contract to support NIAID’s Centers of Excellence for Influenza Research and Response (CEIRR) network. \nSubmit your proposal by April 6\, 2020. If you have any questions\, send them to the contracting officer listed in the solicitation no later than March 4\, 2020. \nLearn more about this funding opportunity in Funding News \n  \nGlobal Biodefense provides this information as a courtesy. Information is subject to change. Please check the funding opportunity sponsor website to verify the most current status. \n 
URL:https://globalbiodefense.com/event/proposals-due-influenza-data-processing-and-outreach/
LOCATION:Global Biodefense Calendar
CATEGORIES:Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200330
DTEND;VALUE=DATE:20200401
DTSTAMP:20200313T155419Z
CREATED:20200304T182006Z
LAST-MODIFIED:20200313T155419Z
UID:40666-1585526400-1585699199@globalbiodefense.com
SUMMARY:SMi’s 22nd Annual Superbugs & Superdrugs - Remote Access Conference
DESCRIPTION:Due to ongoing concerns over COVID-19 this conference is now available with remote access only \nSMi’s 22nd Annual Superbugs & Superdrugs 2020 Conference will be held  30-31 March 2020. \nA Focus on Non-traditional Approaches in the Fight against Antimicrobial Resistance \nSponsored by Scynexis \nCO-CHAIRS FOR 2020: Cara Cassino\, Chief Medical Officer\, Contrafect & Michael Dawson\, Director\, Mike Dawson Antimicrobial Research Consultancy \nAs one of the most impactful pharmaceuticals for maintaining public health\, antibiotics have been around since early 20th century and have since shown a need for significant progress in recent years. This is mainly due to its broad and indiscriminate use which has slowly given birth to multi- to extensively-drug resistant bacteria rendering our current last-resort antibiotic arsenal\, including colistin\, carbapenems\, 3rd and 4th generation cephalosporins\, useless. \nThis year’s event aims to showcase a suite of sessions focused on novel drugs and approaches\, particularly highlighting non-traditional and traditional therapies that provide an innovative means to spearhead the issue. The conference will also place significant emphasis on the much-needed support for innovative approaches such as sessions tackling the funding and support and the regulation that provides guidance towards the goal of ameliorating the continued rise of anti-microbial resistance AMR. \nIt is crucial to bring industry leaders together to discuss the strategies in place that reduce AMR\, evaluate the role pharmaceutical companies and funding bodies play in reducing AMR\, learn about new diagnostics approaches to identify AMR and consider novel candidates and alternatives to anti-microbials. Join us in March 2020\, along with leaders from the pharmaceutical industry\, academia\, regulatory and funding bodies\, and public-private partnerships to discuss the way forward. \nEvent Hashtag: #SMiBugs \nFEATURED SPEAKERS FOR 2020: \n\nYuri Gleba\, Professor\, Founder\, Nomad Bioscience\nMark Albrecht\, Branch Chief\, Antibacterials program\, BARDA/HHS\nPaul Finn\, CEO\, Oxford Drug Design\nCara Cassino\, Chief Medical Officer\, Contrafect\nMartin Everett\, CSO\, Antabio\nSamareh Lajaunias\, Director\, Combioxin SA\nFrancois Moreau\, Scientific Director\, Mutabilis\nEmma Leire\, Microbiology Lead\, Centauri Therapeutics\nLorenzo Corsini\, Co-Founder/CEO/R&D\, Phagomed\nStephen Barat\, VP\, Preclinical Research and Early Development\, Scynexis\nColm Leonard\, Consultant Clinical Adviser/Consultant Thoracic Physician/Honorary Pro\n\nWHATS ON THE AGENDA FOR 2020? \n\nDiscuss the new classes of non-antibiotic antibacterial proteins: Colicins and Colicin-like Bacteriocins from Nomad Bioscience\nGain valuable insight towards fighting severe and resistant infections through neutralising bacterial virulence effectors from Combioxin\nExamine a UK project looking at novel value assessment and reimbursement for novel antimicrobials from NICE/Manchester University NHS Foundation Trust\nExplore direct lytic agents (DLAs) and their potential as a successful disruptive anti-infective technology with Contrafect\nEvaluate the utility of machine learning and AI in antibiotic drug discovery with Oxford Drug Design\n\nGlobal Biodefense is an official media partner of Superbugs & Superdrugs 2020.
URL:https://globalbiodefense.com/event/smis-22nd-annual-superbugs-superdrugs-conference/
LOCATION:Holiday Inn Kensington Forum\, 97 Cromwell Rd\, London\, SW7 4DN\, United Kingdom
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2020/03/superbugs-superdrugs-2020-smi-group.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200326T130000
DTEND;TZID=America/New_York:20200326T143000
DTSTAMP:20200324T160955Z
CREATED:20200324T160607Z
LAST-MODIFIED:20200324T160955Z
UID:42206-1585227600-1585233000@globalbiodefense.com
SUMMARY:APIC AIHA Webinar - Ventilation\, Surface Disinfection and PPE Considerations for the IP and IH
DESCRIPTION:Amidst the flood of information about the COVID-19 pandemic\, one of the greatest risks is missing key intelligence that can protect health and save lives. This town hall-style webinar\, co-hosted by AIHA and the Association for Professionals in Infection Control and Epidemiology (APIC)\, will address occupational health and safety professionals’\, industrial hygienists’ and infection preventionists’ questions about ventilation\, surface disinfection\, respirators\, construction issues\, occupational health and safety during the COVID-19 pandemic.\nFull webinar description. \nAre you a 2020 Full eLearning Subscriber? This webinar is included in your subscription.\nIf you are purchasing this registration for another person\, please contact the eLearning staff at 1-703-849-8888. \nREGISTRATION INFORMATION\nEach person interested in attending needs their own registration. If you are unable to participate live\, you will have access to the recording for 90 days\, and you’ll be notified via email once the recording is available in the Online Classroom.When registering\, please only register once. Once you checkout\, the system will prompt you to sign in with your AIHA credentials\, or to create a new account. Once you complete either process\, you will checkout\, verify your information\, and confirm your order. \nDue to an increased volume of registrations\, please allow an hour to receive the confirmation message. You may need to check your junk folder.
URL:https://globalbiodefense.com/event/apic-aiha-webinar-ventilation-surface-disinfection-and-ppe-considerations-for-the-ip-and-ih/
LOCATION:Webinar
CATEGORIES:Conference,Training,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200326
DTEND;VALUE=DATE:20200331
DTSTAMP:20200312T210424Z
CREATED:20190928T143345Z
LAST-MODIFIED:20200312T210424Z
UID:30707-1585180800-1585612799@globalbiodefense.com
SUMMARY:CANCELLED: Decennial 2020 - International Conference on Healthcare Associated Infections
DESCRIPTION:Notice from organizers 17 March 2020 \nAfter much deliberation and consideration of the Decennial participants’ substantial role in addressing COVID-19 globally\, the Society for Healthcare Epidemiology of America’s Board of Trustees unanimously decided the 6th Decennial International Conference on Healthcare Associated Infections will no longer occur March 26 – 30\, 2020\, in Atlanta\, GA. Centers for Disease Control and Prevention are in agreement with the decision to cancel. Please be patient with us as we navigate through questions\, concerns\, refunds\, and everything in between. Registered participants can find registration refund information and FAQs on the Attendees/Cancellation FAQs page. \nDecennial 2020 – The 6th International Conference on Healthcare Associated Infections will be held 26-30 March 2020 in Atlanta\, Ga. \nHeld once every ten years\, the Decennial Conference reviews the advances of the previous decade and the opportunities and trends for the fields of healthcare epidemiology\, infectious diseases\, and infection prevention and control for the future. \nTopic areas covered at Decennial 2020 include: \n\nAntimicrobial Stewardship Interventions\nHealthcare-Associated Pneumonia/VAE\nAntimicrobial Stewardship Metrics\nHealthcare-Associated Urinary Tract Infections/CAUTI\nOutbreaks and Clusters\nClostridium difficile\nHealthcare-Associated Bloodstream Infections/CLABSI\nDecolonization Strategies\nHealthcare Preparedness\nDiagnostics/Microbiology\nImplementation Science\nInfection Control in Low and Middle-Income Countries\nPublic Reporting of HAIs/Healthcare Epi Policy\nDisinfection and Sterilization of instruments\nInfections in Immunocompromised Patients Quality Assessment\nEmerging Pathogens\nIntravascular Device-Related Infections\nSurgical Site Infections\nEnvironmental Cleaning and Disinfection\nMedical Informatics\nSurveillance\nFungal Infections\nMethodological and Statistical Issues\nViral Infections\nMultidrug-Resistant Gram-Negative Bacteria\nMolecular Epidemiology\n\nPlease visit the Dicennial 2020 website for more information.
URL:https://globalbiodefense.com/event/decennial-2020-international-conference-on-healthcare-associated-infections/
LOCATION:Atlanta Marriott Marquis\, 265 Peachtree Center Ave NE\, Atlanta\, GA\, 30303\, United States
CATEGORIES:Conference
ORGANIZER;CN="The Society for Healthcare Epidemiology of America (SHEA)":MAILTO:info@shea-online.org
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200326
DTEND;VALUE=DATE:20200327
DTSTAMP:20200323T164958Z
CREATED:20200323T164525Z
LAST-MODIFIED:20200323T164958Z
UID:41944-1585180800-1585267199@globalbiodefense.com
SUMMARY:Policy vs. Pandemics: Polarization and Public Health Emergency Preparedness
DESCRIPTION:George Mason University Schar School of Policy and Government Biodefense\, MPP and MPA Programs will co-host a no-fee webinar event\, “Policy vs. Pandemics: Polarization and Public Health Emergency Preparedness” on March 26\, 2020 from 6:00pm – 7:30pm Eastern. \nThe sweeping effects of the on-going COVID-19 pandemic on the social\, economic\, and political framework of the United States highlights the vital importance of a resilient public health infrastructure. In the aftermath of this unprecedented pandemic\, the United States will need to reconsider its approach to biosurveillance\, public health emergency preparedness\, intergovernmental coordination\, and the development of countermeasures in advance of the next health crisis. In the past\, such efforts have been hindered by partisan polarization between Republicans and Democrats\, even as some crucial public health emergency policy was only made possible through bipartisan cooperation. While considering lessons from the past\, this discussion will address bipartisan efforts to move forward on approaches to protect the American people in the future\, such as the implementation of the National Biodefense Strategy. \nDr. Nathan Myers is an associate professor of political science and public administration at Indiana State University. His research interests include public health policy\, U.S. executive branch politics and administration\, emergency planning and preparedness\, and regulation of biotechnology. He is the author of Pandemics and Polarization: Implications of Partisan Budgeting for Responding to Public Health Emergencies (Lexington Books\, 2019). \nDue to the coronavirus pandemic\, this event will be held as a live webinar instead of an in-person talk. Blackboard Collaborate Ultra works best with Google Chrome and does not work with Internet Explorer. Participants will be able to use the “Raise Hand” function in Blackboard Collaborate to ask questions at the end of Dr. Myer’s prepared remarks. \nEveryone who registers for the webinar will receive a 30% discount on his book. \nThis webinar will be recorded and the video will be posted to the YouTube channels for The Pandora Report and the Schar School of Policy and Government . \nIf you have any questions\, please email: biodefense@gmu.edu
URL:https://globalbiodefense.com/event/policy-vs-pandemics-polarization-and-public-health-emergency-preparedness/
LOCATION:Webinar
CATEGORIES:Conference,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200325T150000
DTEND;TZID=America/New_York:20200325T163000
DTSTAMP:20200325T061035Z
CREATED:20200324T060239Z
LAST-MODIFIED:20200325T061035Z
UID:42230-1585148400-1585153800@globalbiodefense.com
SUMMARY:Responding to COVID-19 Webinar: The Science of Social Distancing
DESCRIPTION:Brought to you by the American Public Health Association and the National Academy of Medicine\, The Science of Social Distancing webinar series will explore the state of the science surrounding the current outbreak of COVID-19 in the United States and globally\, with a focus on the emerging evidence on how to best mitigate its impact. Hear from trusted experts in such fields as public health\, infectious disease\, risk communication\, and crisis standards of care. \n\n\nBrought to you by the American Public Health Association and the National Academy of Medicine\, this webinar series will explore the state of the science surrounding the current outbreak of COVID-19 in the United States and globally\, with a focus on the emerging evidence on how to best mitigate its impact. Hear from trusted experts in such fields as public health\, infectious disease\, risk communication\, and crisis standards of care. \nThe webinar will feature a panel of expert speakers\, including: \n\nNancy Messonnier\, MD — Director\, National Center for Immunization and Respiratory Diseases\, Centers for Disease Control and Prevention\nMarc Lipsitch\, DPhil — Director\, Center for Communicable Disease Dynamics\, Harvard T. H. Chan School of Public Health\nMitch Stripling — National Director\, Emergency Preparedness and Response\, Planned Parenthood and former assistant commissioner of Agency Preparedness and Response for New York City\nHoward Markel\, MD\, PhD — George E. Wantz Distinguished Professor of the History of Medicine and Director of the Center for the History of Medicine\, University of Michigan\n\nThe webinar series will draw from and complement existing advisory activities underway at APHA and the National Academies\, including the Standing Committee on Emerging Infectious Diseases and 21st Century Health Threats\, which was convened for the purpose of advising the White House and federal agencies on the U.S. response to COVID-19. \nThe series will rapidly and regularly provide trustworthy scientific analysis of the latest COVID-19 developments for the benefit of policymakers\, public health and health care officials\, and the general public. The series will explore the scientific basis for guidance issued by government\, health and public health organizations\, and industry\, as well as answer questions that are top of mind for its audiences.
URL:https://globalbiodefense.com/event/responding-to-covid-19-webinar-the-science-of-social-distancing/
LOCATION:Virtual-Webcast
CATEGORIES:Conference,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200324
DTEND;VALUE=DATE:20200326
DTSTAMP:20200323T210103Z
CREATED:20200319T205750Z
LAST-MODIFIED:20200323T210103Z
UID:42054-1585008000-1585180799@globalbiodefense.com
SUMMARY:BIO Coronavirus Collaboration Initiative Virtual Summit
DESCRIPTION:The Biotechnology Innovation Organization (BIO) is hosting a virtual summit to help companies working on COVID-19 treatments\, diagnostics and vaccines to come together to discuss challenges and opportunities with government officials and other stakeholders. \nThe two-day summit will take place on Tuesday\, March 24 and Wednesday\, March 25\, and will be led by BIO President and CEO Jim Greenwood and Dr. George Scangos\, President and CEO of Vir Biotechnology. BIO Board Chairman Dr. Jeremy Levin\, CEO of Ovid Therapeutics\, appointed Dr. Scangos to oversee the BIO Coronavirus Collaboration Initiative\, which is intended to help connect innovators with partners across both the industry and inside the federal government to combat the coronavirus. \nThe summit will include leaders from biotech and pharmaceutical companies\, global academic experts in virology and immunology\, and non-governmental organizations. Those invited to participate include Ambassador Deborah Birx\, Dr. Robert Kadlec\, and other senior leaders from key government offices\, including the U.S. Department of Defense\, U.S. Department of Health & Human Services\, the Centers for Disease Control and Prevention\, National Institutes of Health\, and the Food and Drug Administration. Information regarding confirmed guests will be provided at a later date. \nAs an international trade association representing more than 700 biotechnology companies\, BIO is playing a unique role in organizing and coordinating the activities of many of its companies. More than 45 member companies are working to address coronavirus and more than 20 have products in various stages of development. \n“Close collaboration between America’s biopharmaceutical companies and the U.S. government is leading the global race to develop vaccines and cures to protect society from the coronavirus\,” said BIO President and CEO Jim Greenwood. “Our researchers and scientists are at the forefront of this important effort\, and they will answer the challenge just as they always have. This virtual summit is a critical step to helping industry leaders\, government officials\, and other vital partners collaborate and ultimately accelerate the development of new medicines to overcome this global threat. BIO is uniquely positioned to help drive this collaboration\, and this is one step in our broader efforts to combat the coronavirus.” \n“Across the biopharmaceutical industry\, men and women are working tirelessly under difficult circumstances to combat the coronavirus\,” said Dr. Scangos.“We are witnessing the true motivation of people in the industry – to do everything we can to bring medicines to people who need them. I am gratified to see people working incredibly hard to bring forward treatments for Covid-19 as quickly as humanly possible. I am pleased to help lead this virtual summit\, which will help facilitate the collaboration and public-private partnerships necessary to treat the sick and prevent further spread of the coronavirus.” \nThe virtual summit will feature presentations and discussions on the latest epidemiologic developments related to the coronavirus\, response work that is underway\, and where critical gaps exist in current R&D and response efforts. The meeting will focus on three key areas of the response: diagnosing the virus\, treating those with the virus\, and preventative measures to contain further transmission of the virus.
URL:https://globalbiodefense.com/event/bio-coronavirus-collaboration-initiative-virtual-summit/
LOCATION:Webinar
CATEGORIES:Conference,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200324
DTEND;VALUE=DATE:20200325
DTSTAMP:20200323T203331Z
CREATED:20191211T055500Z
LAST-MODIFIED:20200323T203331Z
UID:35083-1585008000-1585094399@globalbiodefense.com
SUMMARY:The Role of Digital Health Technologies in Drug Development - Webcast
DESCRIPTION:The Role of Digital Health Technologies in Drug Development: A Workshop will be webcast on March 24\, 2020. \nAs digital health technologies (e.g. smartphone apps\, wearables\, and mobile-device-based tools) – hardware and software – become increasingly available to consumers\, providers\, and researchers\, there are new opportunities to address critical barriers or “pain points\,” better connect patients and health care providers\, and incorporate patient input throughout the drug research and development (R&D) life cycle. However\, a lack of clarity when it comes to the evaluation\, selection\, and implementation of digital health technologies has impeded the practical application of these innovations. Lessons learned from the direct-to-consumer genomics industry\, which has been increasingly moving into the clinical health space over the last 10 years\, may help inform the integration of digital health technologies into drug R&D. \nThis workshop will provide a venue to discuss challenges and opportunities in digital health technologies for improving the probability of success in drug development and enabling precision medicine. Workshop participants may consider key components for an evidence-based framework for applying digital health technologies towards drug research and development. \nThe Forum on Drug Discovery\, Development\, and Translation and the Roundtable on Genomics and Precision Health will host a public workshop on March 24\, 2020 which will feature invited presentations and discussions to: \nDiscuss challenges/questions that digital health technologies may be uniquely suited to address and opportunities for digital health technologies to enable better patient care and more efficient clinical trials; \nConsider strategies for evaluating and selecting digital health technologies that are fit-for-purpose in drug development (e.g. establishing appropriate evidentiary criteria); \nDiscuss privacy\, ethical\, and regulatory issues related to the use of digital health technologies; \nExamine currently validated and/or FDA-approved drug development applications for digital health technologies; \nConsider opportunities to enable the practical application of digital health technologies for improving drug development (e.g. sharing best practices for the validation and use of digital health technologies\, harmonizing guidelines across sectors).
URL:https://globalbiodefense.com/event/the-role-of-digital-health-technologies-in-drug-development-webcast/
LOCATION:Webinar
CATEGORIES:Webinar-Webcast,Workshop
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20200321T100000
DTEND;TZID=America/Toronto:20200321T180000
DTSTAMP:20200203T162942Z
CREATED:20200203T162408Z
LAST-MODIFIED:20200203T162942Z
UID:38416-1584784800-1584813600@globalbiodefense.com
SUMMARY:University of Toronto Global Health & AI Challenge
DESCRIPTION:HOW WILL YOU AND YOUR TEAM USE AI TO SOLVE SOME OF THE MOST COMPLEX GLOBAL HEALTH CHALLENGES\n\n\n\nThe Global Health & AI Challenge\, a partnership between the Dalla Lana School of Public Health and Vector Institute will engage students in critical dialogue and problem-solving scenarios on some of the most complex global health challenges of our time. The top ten threats to global health in 2019 include the climate crisis and air pollution; noncommunicable diseases; an impending influenza pandemic; fragile settings; antimicrobial resistance; high-threat pathogens; inadequate primary health care; vaccine hesitancy; the growing threat of dengue; and the HIV epidemic . All threats to global health exist due to complex\, interrelated economic\, political\, social\, environmental\, and historical factors\, and thus demand creative\, interdisciplinary and intersectoral solutions. Technological innovations and interventions such as AI offer the potential to disrupt these complex threats\, and teams will be tasked with developing solutions that harness the power of AI and machine learning. \n***REGISTRATION DEADLINE IS DECEMBER 8TH\, 2019. SPOTS ARE LIMITED*** \nGlobal Health & AI Challenge Objectives \n\nOffer students local\, accessible experiential and entrepreneurial learning opportunities in global health\nEnhance student learning outcomes around ethical design thinking\, communication\, problem solving\, innovation\, and applying technical skills and AI\nExpand students’ knowledge of the complexity of global health threats and the application of AI-related methodologies and their limitations\nFacilitate student networking and career exploration opportunities\n\nWhat to expect? \n\nJoin a multi-disciplinary team of students to select and tackle a global health challenge.\nApply principles of ethical design thinking to prototype solutions using AI and machine learning.\nAccess an expert team advisor for additional mentorship and guidance.\nCompete to win a team prize of a $500 honorarium\, the opportunity to present your solution to relevant stakeholders (may include investment partners\, organizations or leading experts)\, $100 gift cards to App Store and iTunes\n\nWho can participate? \nThe Global Health & AI Challenge will be open only to current University of Toronto graduate students. Students will be able to sign up individually or in pairs and will then be matched up with students from other programs to ensure teams are multidisciplinary. \nTeams must include at least one student studying in each of the following programs: \n\nDalla Lana School of Public Health (DLSPH)\, including Public Health Sciences & IHPME\nSTEM programs such as Computer Science and Engineering\nRotman School of Management\n\nGraduate students pursuing other programs of study are also encouraged to apply along with a brief statement of interest of no more than 250 words. The optimal number of multidisciplinary teams for this year will be between 6-10\, with 4-6 participants on each team. Students will be able to sign up individually or in pairs and will then be matched up with students from other programs to ensure teams are multidisciplinary. There will be a $25 fee for each student to sign up. \n***REGISTRATION DEADLINE IS DECEMBER 8TH\, 2019. SPOTS ARE LIMITED*** \nTimeline \n\nDecember 8th – deadline for students to apply as individuals or in pairs\nDecember 16th – during this week participating students will be invited to a kickoff introduction event to meet their teammates from other programs.\nJanuary 12th – Teams will submit their initial global health problem identification proposal\nMid January/Early February – Teams will be invited to professional development workshops focused on global health & AI\, design thinking and ethics to apply to their own global health challenge\nFebruary – Each team will be assigned expert team advisor to meet with to provide additional mentorship and guidance.\nMarch 21st – All teams will present their global health challenge and solutions to a panel of judges and stakeholders.\n\nFor more information please contact ghoffice.dlsph@utoronto.ca \n#GHAIChallenge #GlobalHealthDLSPH #VectorInst
URL:https://globalbiodefense.com/event/university-of-toronto-global-health-ai-challenge/
LOCATION:Health Sciences Building\, 155 College Street\, Room 507\, TORONTO\, ON\, M5T 3M7\, Canada
CATEGORIES:Innovation Challenge
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2020/02/0299fad3c83db38250c5b87494431a50.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200318T100000
DTEND;TZID=America/New_York:20200318T154500
DTSTAMP:20200210T161026Z
CREATED:20200210T160543Z
LAST-MODIFIED:20200210T161026Z
UID:39238-1584525600-1584546300@globalbiodefense.com
SUMMARY:Next Evolution: Overhauling Key Elements of Biodefense
DESCRIPTION:The Bipartisan Commission on Biodefense will convene a meeting entitled ‘Next Evolution: Overhauling Key Elements of Biodefense‘ on March 18\, 2020 in Washington D.C. and made available by webcast. \nThis meeting aims to inform the assessment of biodefense programs with structural challenges that impede the government’s ability to safeguard the Nation. \nTopics to be discussed at this meeting include the: \n\nSelect Agent Program\nBioWatch Program\nHospital Preparedness Program\n\nSpeakers will share their perspectives\, experiences\, challenges\, and recommended solutions with regard to federal biodetection\, pathogen security\, and hospital preparedness programs. \nRegistration is required and attendance is free. \nWednesday\, March 18\, 2020 \n10:00 AM – 3:45 PM \nHudson Institute \n1201 Pennsylvania Avenue\, NW\, 4th floor \nWashington\, DC 20004 \nSee map \n  \n 
URL:https://globalbiodefense.com/event/next-evolution-overhauling-key-elements-of-biodefense/
LOCATION:Hudson Institute\, 1201 Pennsylvania Avenue Northwest\, #400\, Washington\, DC\, 20004\, United States
CATEGORIES:Conference,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200316
DTEND;VALUE=DATE:20200318
DTSTAMP:20200223T181226Z
CREATED:20200223T173102Z
LAST-MODIFIED:20200223T181226Z
UID:40151-1584316800-1584489599@globalbiodefense.com
SUMMARY:IABS-CEPI Vaccine Technology Platforms Meeting
DESCRIPTION:A cross-learning symposium on vaccine licensure based on technology platforms\, the IABS-CEPI-ZAPI Technology Platforms Meeting\, will take place 16-17 March 2020 in Brussels\, Belgium. \nThe scientific committee for this workshop is co-Chaired by: \n\nDaniel Brasseur\, former CHMP-PDCO-VWP chair at EMA; CEPI consultant\nMurray Lumpkin\, former Deputy Director\, FDA; Bill & Melinda Gates Foundation\n\nHighlighted topics of interest on the agenda include: \n\nWHO regulatory preparedness activities to facilitate access to emergency vaccines\nHuman influenza vaccine successes and failures\nLessons for emergency preparedness leaned from Ebola vaccine development and licensure\nRegulatory approach to vaccine tech platforms: FDA perspective\, EU approach\, AVAREF\, Asian regulators\nAdvanced human vaccines in the pipeline (viral vectors\, VSV-Measles-ChAd…) and RNA\, DNA technologies\nTo what extent can clinical trials be pre-arranged?\nDetermining what is platform generic vs. platform specific in manufacturing and quality control\nChallenges to prove vaccine efficacy for outbreak vaccines and mitigating risk\nStreamlining regulatory acceptance from ‘tried and true’ vaccine platforms\n\nIn addition\, CEPI will review its current portfolio and examples of vaccine candidates based on technology platforms. \nMembers of the Scientific Committee include: \n\nDr. Barney Graham\, NIH\, Deputy Director and Chief\, Viral Pathogenesis Laboratory\nDr. Mélanie Saville\, Director\, Vaccine Development\, CEPI\nProf. Dr. Johan Neyts\, Rega Institute Louvain\, Belgium\, specialist of DNA vaccine PLLAV\nDr. Marion Gruber\, FDA\, Director\, Office of Vaccine Research and Review – CBER\nDr. Ivo Classen\, EMA\, Head of Veterinary Medicines Division\nDr. Marco Cavaleri\, EMA\, Head of Anti-infectives and Vaccines\nProf Dr. Jeffery Almond\, Oxford University; Chairman of the Board\, Osivax\nDr. Jean-Christophe Audonnet\, Senior Director\, Vaccines R&D; ZAPI Project Coordinator;\nBoehringer Ingelheim Animal Health\nDr. Emmanuel Hanon\, Senior Vice President\, Head of R&D\, GSK Vaccines\nDr Ajoy Chakrabarti\, Bill & Melinda Gates Foundation Vaccine Development\nDr Steve Black\, The Brighton Collaboration\, Task Force for Global Health\n\nRegister now for the IABS-CEPI Technology Platforms Meeting
URL:https://globalbiodefense.com/event/iabs-cepi-vaccine-technology-platforms-meeting/
CATEGORIES:Conference,Industry Day
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200312T130000
DTEND;TZID=America/New_York:20200312T143000
DTSTAMP:20200220T011222Z
CREATED:20200220T010949Z
LAST-MODIFIED:20200220T011222Z
UID:39863-1584018000-1584023400@globalbiodefense.com
SUMMARY:Center for the Study of WMD Spotlight Seminar: Coronavirus and Biosecurity
DESCRIPTION:The outbreak of the deadly coronavirus is the latest global health crisis to capture the headlines and the fears of the world. With daily updates from health officials\, there is both a surfeit of information and plenty of misinformation about the disease\, its spread\, and its origin. \nPlease join us at the Center for the Study of Weapons of Mass Destruction March Spotlight Seminar on “Coronavirus and Biosecurity.” The panel will feature experts in the fields of bioterrorism\, biosurveillance\, and infectious disease who can provide timely context for the outbreak. Panelists will assess the response to the public health emergency by the United States and China and discuss what this novel coronavirus may teach us for future natural and intentional biological events. \nIf you have any questions about the event\, please contact the CSWMD Admin staff at CSWMD-Admin@ndu.edu or call 202-433-6382. \nBiographies:\nDr. Gigi Gronvall is a Senior Scholar at the Johns Hopkins Center for Health Security and an Associate Professor in the Department of Environmental Health and Engineering at the Johns Hopkins Bloomberg School of Public Health. She is an immunologist by training. Dr. Gronvall’s work at the Center for Health Security addresses the role of scientists in health security—how they can contribute to an effective technical response against a biological weapon or a natural epidemic. She is particularly interested in developing policies that will boost the safety and security of biological science activities while allowing beneficial research to flourish. Dr. Gronvall is the author of the books Synthetic Biology: Safety\, Security\, and Promise and Preparing for Bioterrorism: The Alfred P. Sloan Foundation’s Leadership in Biosecurity. \nDr. Noreen Hynes has more than 40 years of medical and public health experience in both international and domestic settings. She is a physician trained in internal medicine\, infectious diseases\, tropical medicine\, and epidemiology. Prior to her medical education\, Dr. Hynes served as a Peace Corps Volunteer in Tunisia\, followed by serving as a Foreign Service Officer in Mali and Cote d’Ivoire\, and then received a master of public health degree from Johns Hopkins University. After earning a medical degree from the Uniformed Services University of the Health Sciences in Bethesda\, MD\, Dr. Hynes completed a residency in internal medicine and a fellowship in infectious diseases at the Massachusetts General Hospital/Harvard Medical School. As a Commissioned Officer in the U.S. Public Health Service\, Dr. Hynes’ duty stations included Atlanta (Epidemic Intelligence Service)\, Colorado\, Arkansas\, Baltimore\, and Washington D.C. Following the events of late 2001\, she served as senior advisor to the Vice President of the United States for Medicine and Public Health (Homeland Security). Prior to retirement from government service in 2007\, Dr. Hynes was the deputy assistant secretary for Public Health Emergency Preparedness and the director of the Office of Public Health Emergency Medical Countermeasures (now the Biomedical Advanced Research and Development Authority – BARDA) at the US Department of Health and Human Services. Since 1997\, Dr. Hynes has been a part-time faculty member at the Johns Hopkins University Schools of Medicine and Public Health. She directs the Geographic Medicine Center of the Division of Infectious Diseases and serves as the associate medical director of the Biocontainment Unit of the Johns Hopkins Hospital — a unit focused on the care of patients with high consequence pathogens\, such as Ebola. At the Bloomberg School of Public Health\, Dr. Hynes co-directs the infectious diseases concentration in the master of public health program and co-teaches a course focused on the science\, public health and policy aspects of chemical and biological weapons. Her research focuses on vaccine-preventable diseases\, tropical diseases\, zoonotic infections\, and high consequence pathogens. \nDr. Rohit Chitale joined DARPA as a program manager in 2019. He is an infectious disease epidemiologist with more than 20 years of experience helping national and international organizations establish and lead programs related to infectious disease prevention and eradication\, with specific expertise in the design and implementation of disease surveillance systems and the development of new disease control tools. Before coming to DARPA\, Dr. Chitale co-established the Global Disease Detection Operations Center at the U.S. Centers for Disease Control and Prevention (CDC)\, the first event-based all-hazards surveillance unit at the CDC. He also served as the CDC Country Director in the Republic of South Sudan. In a prior role at the U.S. Department of Defense (DoD)\, he established and led the Division of Integrated Biosurveillance within the Armed Forces Health Surveillance Center to address capability gaps in DoD biosurveillance and global health security operations. In that role\, he led efforts to integrate syndromic\, case-based\, and event-based disease surveillance systems across civilian\, military\, and veteran populations to decrease the time to disease detection\, diagnosis\, and treatment. While at DoD\, he helped write the Global Health Security Agenda legislation. Previously\, at the Johns Hopkins Bloomberg School of Public Health\, Dr. Chitale co-created The MENTOR Initiative — a public-private partnership designed to test and evaluate (pre-clinical\, Phase I\, II\, and III trials) new vector-borne disease control technologies.
URL:https://globalbiodefense.com/event/center-for-the-study-of-wmd-spotlight-seminar-coronavirus-and-biosecurity/
LOCATION:National Defense University\, 300 5th Avenue SW\, Washington\, DC\, 20319\, United States
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200310T133000
DTEND;TZID=America/New_York:20200310T143000
DTSTAMP:20240623T230635Z
CREATED:20200305T230620Z
LAST-MODIFIED:20240623T230635Z
UID:40918-1583847000-1583850600@globalbiodefense.com
SUMMARY:Journalists Covering COVID-19: What Do You Need to Know
DESCRIPTION:Association of Health Care Journalists (AHCJ) members are invited to a special webcast event “Covering COVID-19: What Do You Need to Know?” on 10 March 2020. \nThe COVID-19 outbreak story is evolving quickly and there are many unknowns about the epidemic\, including how contagious the virus is\, its mortality rate and whether there is undetected spread occurring outside of China. Providing accurate information to the public is more important than ever in this moment of uncertainty. Hear a panel of infectious disease experts and a journalist explain what is known\, what to watch out for\, where to find trusted resources and how to combat misinformation and confusion. \n\nMaryn McKenna\, independent journalist\, author; Senior Fellow of the Center for the Study of Human Health at Emory University\nMichael Osterholm\, Ph.D.\, M.P.A.\, director\, Center for Infectious Disease Research and Policy\nSaskia Popescu\, senior infection preventionist\, ELBI Fellow and managing editor; HonorHealth\, Johns Hopkins Center for Health Security\, Pandora Report\nAngie Rasmussen\, Ph.D.\, Columbia University Mailman School of Public Health\, Associate Research Scientist\nModerator: Bara Vaida\, AHCJ core topic leader/infectious diseases\n\nSaskia Popescu is an experienced infectious disease epidemiologist and infection preventionist with a strong background in project management\, translation of complex issues into frontline applications\, and enhancing healthcare biopreparedness. She is passionate about healthcare biopreparedness\, antimicrobial resistance\, and driving change across sectors in global health security. \nAngie Rasmussen\, Ph.D.\, is an associate research scientist at Columbia University’s Mailman School of Public Health. She is a virologist studying host responses to infection by combining classical virology with modern systems biology approaches. Her research objectives are to identify host response signatures predictive of infection severity or disease outcome and host pathways to target drug development or repurposing. She is particularly interested in viruses that are highly pathogenic\, newly emergent or likely to emerge because of climate change\, land development\, or ecological disruption. \nMaryn McKenna is a journalist and book author and teaches health and science writing and storytelling\, and media literacy. She has reported from epidemics and disasters\, and farms and food production sites\, on most of the world’s continents\, including a field hospital in New Orleans during Hurricane Katrina\, to Midwestern farms devastated by the 2015 epidemic of avian flu. She writes for The New York Times Magazine\, The New Republic\, WIRED\, Smithsonian\, The Atlantic\, NPR\, and numerous other magazines and sites. She is the author of the 2017 bestseller Big Chicken: The Incredible Story of How Antibiotics Created Modern Agriculture and Changed the Way the World Eats (National Geographic Books\, Sept. 2017)\, which received the 2018 Science in Society Award\, making her a two-time winner of that prize. \nPlease visit the AHCJ’s Covering COVID-19: What Do You Need to Know event website for more information.
URL:https://globalbiodefense.com/event/journalists-covering-covid-19-what-do-you-need-to-know/
CATEGORIES:Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20200303T103000
DTEND;TZID=Europe/London:20200305T132000
DTSTAMP:20200203T163102Z
CREATED:20200203T162235Z
LAST-MODIFIED:20200203T163102Z
UID:38411-1583231400-1583414400@globalbiodefense.com
SUMMARY:National Museum of Scotland Outbreak Lab Workshop
DESCRIPTION:In this hands‐on\, experimental workshop\, pupils will use real laboratory techniques from Easter Bush Science Outreach Centre to track the outbreak of an infectious\, parasitic disease.  \nSuitable for: S1–3 \nCost: Free of charge   \nNo of pupils: 24 per session max \nTimings: 10:30–13:00 or 11:00–13:30  \n(60 minute workshop\, 60 minute exhibition & gallery visit) \nDates: Tue 3–Thu 5 Mar 2020  \nIn this hands‐on\, experimental workshop\, pupils will use real laboratory techniques from Easter Bush Science Outreach Centre to track the outbreak of an infectious\, parasitic disease.  \n They will use micropipettes and other lab equipment to perform a mock diagnostic test\, supported by scientists from The Roslin Institute and Edinburgh Infectious Diseases. Pupils will work as a group to interpret their results and agree on a recommended course of action.  \n The session l also covers some of the science behind disease diagnosis and how parasitic diseases can spread between animals and humans\, and gives pupils the opportunity to meet and interact with professional scientists who are working on infectious diseases.  \n Class A  \n10:30–11:30 – Workshop  \n11:30–12:00 – Visit Parasites exhibition  \n12:00–12:30 – Visit Science & Technology galleries  \n12:30–13:00 – Lunch (space set aside in lunchroom for packed lunches) \n Class B \n11:00–11:30 – Visit Parasites exhibition \n11:30–12:00 – Visit Science & Technology galleries  \n12:00–12:30 – Lunch (space set aside in lunchroom for packed lunches) \n12:30–13:30 – Workshop  \nThis event is run in partnership with the University of Edinburgh’s Roslin Institute\, Easter Bush Science Outreach Centre and Edinburgh Infectious Diseases. \nClasses must be accompanied by a teacher.  \nBy reserving 1 timeslot\, you can bring up to 24 pupils. If you are bringing less than 24\, please let us know on the booking form and we may combine with a small class from a different school.  \n\nTravel Subsidy \nThe University of Edinburgh is able to provide some financial support towards travel expenses for schools attending this workshop. This is specifically targeted at state schools in deprived areas\, where more than 45% of pupils are in the lowest 20% SIMD category. The support would be up to a max of £200 per school. This is available on a first come\, first served basis. Please enquire upon booking for further information.
URL:https://globalbiodefense.com/event/outbreak-lab-workshop/
LOCATION:National Museum of Scotland\, Chambers Street\, Edinburgh\, Scotland\, EH1 1JF\, United Kingdom
CATEGORIES:Workshop
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2020/02/1687fc97b850305839f2659d50c82977-scaled.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200303
DTEND;VALUE=DATE:20200306
DTSTAMP:20191227T222008Z
CREATED:20191115T214342Z
LAST-MODIFIED:20191227T222008Z
UID:36020-1583193600-1583452799@globalbiodefense.com
SUMMARY:Mitigating the Impact of Blast-related Burn Injuries: From Prolonged Field Care to Rehabilitation and Resilience
DESCRIPTION:The 9th DoD State-of-the-Science Meeting on Blast Injury Research will be held March 3-5\, 2020 in Arlington\, Virginia. \nThe meeting will address epidemiology and outcomes of blast-related burn injuries; prevention and acute management of blast-related burn injuries; prolonged field care and chronic care; and transforming research. \nThis meeting is sponsored by the DoD Blast Injury Research Coordinating Office\, U.S. Army Medical Research and Development Command\, on behalf of the DoD Executive Agent for Medical Research for Prevention\, Mitigation\, and Treatment of Blast Injuries. \nThe event is presented by the RAND National Security Research Division (NSRD)\, which conducts research and analysis for all national security sponsors other than the U.S. Air Force and the Army. The division includes the National Defense Research Institute\, a federally funded research and development center whose sponsors include the Office of the Secretary of Defense\, the Joint Staff\, the Unified Combatant Commands\, the defense agencies\, and the Department of the Navy. NSRD also conducts research for the U.S. intelligence community and the ministries of defense of U.S. allies and partners. \nThis will be a working meeting. Over 100 subject matter experts from the DoD\, other Federal agencies\, academia\, industry\, and the international community are expected to participate. \nAttendance is free\, first come-first serve\, and capped at 150. There are no continuing education credits\, and participants are responsible for their own travel\, lodging\, and expenses. \nEDITOR’S UPDATE: Registration for the Ninth State-of-the-Science Meeting is now full. If you would like to be added to the waitlist\, contact the event organizers here.
URL:https://globalbiodefense.com/event/mitigating-the-impact-of-blast-related-burn-injuries-from-prolonged-field-care-to-rehabilitation-and-resilience/
LOCATION:RAND’s Pentagon City Office\, 4th Floor\, 1200 South Hayes Street\, Arlington\, VA\, 22202-5050\, United States
CATEGORIES:Conference,Government Hosted
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200302T140000
DTEND;TZID=America/New_York:20200302T150000
DTSTAMP:20200126T224530Z
CREATED:20200126T224350Z
LAST-MODIFIED:20200126T224530Z
UID:37784-1583157600-1583161200@globalbiodefense.com
SUMMARY:CDC National Call Series on Novel Coronavirus Monitoring & Preparedness
DESCRIPTION:The Centers for Disease Control and Prevention (CDC) is closely monitoring an outbreak caused by a novel (new) coronavirus in Wuhan City\, Hubei Province\, China. A number of countries\, including the U.S.\, are actively screening incoming travelers from Wuhan. \nStarting January 21\, 2020\, CDC’s 2019 Novel Coronavirus (2019-nCoV) response team will host a series of national calls to continue providing state and local partners with the latest information on the novel coronavirus outbreak and U.S. preparedness efforts. \nThe call schedule is currently set as follows: \n\n21 January 2:00-3:00pm EST\n27 January 2:00-3:00pm EST\n3 February 2:00-3:00pm EST\n10 February 2:00-3:00pm EST\n24 February 2:00-3:00pm EST\n2 March 2:00-3:00pm EST\n\n  \nParticipant Information \nBridgeline: \n1(800)-857-6697 Participant \nPasscode: 1324420 \nIf you have any questions about the call series\, please contact the CDC State Coordination Task Force (SCTF) – Operations. \nh/t NACCHO for originally posting this information.
URL:https://globalbiodefense.com/event/cdc-national-call-series-on-novel-coronavirus-monitoring-preparedness-5/
CATEGORIES:Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200302T113000
DTEND;TZID=America/New_York:20200302T120000
DTSTAMP:20200301T230419Z
CREATED:20200301T230209Z
LAST-MODIFIED:20200301T230419Z
UID:40566-1583148600-1583150400@globalbiodefense.com
SUMMARY:COVID-19 Live Webcast with Johns Hopkins Experts
DESCRIPTION:With COVID-19 now spreading via community transmission in the U.S. and the World Health Organization raising its risk assessment to “very high\,” the Johns Hopkins Bloomberg School of Public Health will host a 30-minute webcast featuring some of the best minds addressing this global health concern. \nYou’ll hear from Dr. Jennifer Nuzzo and Dr. Tara Kirk Sell of the Johns Hopkins Center for Health Security and Lauren Sauer of the Johns Hopkins Office of Critical Event Preparedness and Response. The conversation will be moderated by Dr. Joshua Sharfstein\, Vice Dean of the Johns Hopkins Bloomberg School of Public Health and former secretary of Maryland’s Department of Health. \nThey’ll discuss the findings of the Global Health Security Index referenced by President Trump last week\, what you need to know about community transmission and how to protect yourself from misinformation. They will also answer viewer questions submitted before and during the broadcast. \nSpeakers\n\nJennifer Nuzzo\, DrPH\, SM\nSenior Scholar\, Johns Hopkins Center for Health Security\nJohns Hopkins Bloomberg School of Public Health\nTara Kirk Sell\, PhD\, MA\nSenior Scholar\, Johns Hopkins Center for Health Security\nJohns Hopkins Bloomberg School of Public Health\nLauren M. Sauer\, MS\nDirector of Operations\, Johns Hopkins Office of Critical Event Preparedness and Response\nJohns Hopkins University School of Medicine\nJosh Sharfstein\, MD\nModerator\nVice Dean for Public Health Practice and Community Engagement\nJohns Hopkins Bloomberg School of Public Health\n\nA recording will be made available via on The Hub’s dedicated coronavirus page at https://hub.jhu.edu/novel-coronavirus-information/ and across Bloomberg School channels. \nThe Johns Hopkins Bloomberg School of Public Health will host additional webcasts as the coronavirus outbreak continues. Follow us on Twitter\, Facebook\, LinkedIn\, and Instagram to be notified about future broadcasts. \nThe Bloomberg School is also launching a daily “Public Health On Call” podcast with an immediate focus on the coronavirus outbreak. Subscribe via YouTube or Libsyn.
URL:https://globalbiodefense.com/event/covid-19-live-webcast-with-johns-hopkins-experts/
CATEGORIES:Conference,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200229
DTEND;VALUE=DATE:20200305
DTSTAMP:20200210T165602Z
CREATED:20200210T162700Z
LAST-MODIFIED:20200210T165602Z
UID:39241-1582934400-1583366399@globalbiodefense.com
SUMMARY:16th CDC International Symposium on Biosafety
DESCRIPTION:The 16th CDC International Symposium on Biosafety – Laboratory Safety and Security for Clinical\, Public Health\, Research and Animal Care will be held 29 February – 4 March\, 2020 in Atlanta\, Georgia. \nStakeholders will learn about the soon-to-be-released 6th edition of the BMBL\, gaps in clinical and research biosafety\, risk management tools for animal facilities\, virtual reality training\, poliovirus containment\, and more. \nHighlighted sessions include: \n\nExperiences Coordinating Laboratory Policies and Procedures at CDC \nSteve Monroe\, PhD\, Centers for Disease Control and Prevention\nLaboratory Emergency Response Plans: A Team Approach\nPatrick Stockton\, MS\, RBP\, University of Georgia (Biosafety)\, Steve Harris\, University of Georgia (Emergency Preparedness)\, Captain Adam Fouche\, University of Georgia (Police)\, and Roger L. Evans\, Athens Clark County (Fire)\nLessons Learned in Risk Assessment for the Laboratory and Beyond\nRyan Ritterson\, PhD\, Gryphon Scientific\nIssues in Operation and Decontamination in Animal Research Facilities\nJason Villano\, DVM\, MSc\, MS\, DACLAM\, Johns Hopkins University \nDecontamination in the Clinical Laboratory: A Unique Environment\nSheldon Campbell\, MD\, PhD\, FCAP\, Yale School of Medicine\nUsing Risk Assessment to Identify\, Evaluate and Prioritize Facility Repairs\nJohn R. Henneman\, M.S.\, RBP/ABSA\, Biosecurity Research Institute and Miguel A. Grimaldo\, M. Eng\, University of Texas Medical Branch\n\nPlease visit the Eagleson Institute’s CDC Biosafety Symposium website for more information and to register.
URL:https://globalbiodefense.com/event/16th-cdc-international-symposium-on-biosafety/
LOCATION:Westin Perimeter North Hotel\, 7 Concourse Pkwy NE\, Atlanta\, GA\, 30328\, United States
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20200228T140000
DTEND;TZID=Europe/London:20200228T170000
DTSTAMP:20200203T163127Z
CREATED:20200203T162156Z
LAST-MODIFIED:20200203T163127Z
UID:38406-1582898400-1582909200@globalbiodefense.com
SUMMARY:Faculty of Natural Sciences Research Seminar: Infectious Diseases
DESCRIPTION:Join the next FoNS Research Seminar and learn the cutting-edge research on infectious diseases taking place across the Faculty\n\n\n\nThe Faculty regularly organises events that showcase its strong research areas in order to stimulate new collaborations and discussions around a topic. The next one will be on the topic of “Infectious Diseases”. Our highlighted speakers are: \n\nProf. Ed Tate\, Professor in Chemical Biology\, Department of Chemistry\n\n\nDr Anna Barnard\, Sir Henry Dale Fellow\, Department of Chemistry\n\n\nDr Abigail Clements\, Lecturer\, Department of Life Sciences\n\n\nDr Gerald Larrouy-Maumus\, Senior Lecturer\, Department of Life Sciences\n\n\nDr Oliver Ratmann\, Lecturer in Statistics\, Department of Mathematics\n\nPhD students and postdocs will also participate at this event and their names will be announced very soon. Note there will be a drinks & canapes reception afterwards! \nFor further details about this event\, please see the event’s website.
URL:https://globalbiodefense.com/event/faculty-of-natural-sciences-research-seminar-infectious-diseases/
LOCATION:Imperial College London\, Sir Alexander Fleming Building G34 LT\, Exhibition Road\, London\, SW7 2AZ\, United Kingdom
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2020/02/89a4e54954d51d64e4de06a176f38c9a.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200228
DTEND;VALUE=DATE:20200229
DTSTAMP:20200211T234244Z
CREATED:20200211T234042Z
LAST-MODIFIED:20200211T234244Z
UID:39305-1582848000-1582934399@globalbiodefense.com
SUMMARY:Deadline for NIAID BAA Proposals: Advanced Development of Vaccine Candidates for Acute Flaccid Myelitis (AFM) Associated With Enterovirus D68
DESCRIPTION:HHS-NIH-NIAID-BAA2020-1\nResearch Area 002: Advanced Development of Vaccine Candidates for Acute Flaccid Myelitis (AFM) Associated With Enterovirus D68\nSupports the development of inactivated Enterovirus D68 vaccines\, preferably using adjuvants that minimize regulatory concerns and expedite vaccine development into a Phase I clinical trial. \nDue Date: February 28\, 2020\, by 3 p.m. Eastern Time \n  \nLearn more about this opportunity in Funding News. \n  \nGlobal Biodefense provides this information as a courtesy. Information is subject to change. Please check the funding opportunity sponsor website to verify the most current status.
URL:https://globalbiodefense.com/event/deadline-for-niaid-baa-proposals-advanced-development-of-vaccine-candidates-for-acute-flaccid-myelitis-afm-associated-with-enterovirus-d68/
LOCATION:Global Biodefense Calendar
CATEGORIES:Deadlines
END:VEVENT
END:VCALENDAR